Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
Other Non-Commercial Sponsor
The Hospital for Sick Children
Participants in this trial will be randomised into one of two treatment arms. Arm A will include 68 weeks of single agent Vinblastine administered once weekly IV. Arm B will include 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.